Cat#: | RP-1782H |
Product Name: | Recombinant Human Erythropoietin / EPO Protein |
Synonym: | EPO, EP, Erythropoietin, Erythropoetin, Erthropoyetin, Hematopoietin, Hemopoietin, rhEPO, MVCD3 |
Source: | HEK293 |
Molecular Characterization: | Recombinant Human EPO / Erythropoietin protein has a calculated M.W. of 18.4 kDa. DTT-reduced protein migrates as 30-37 kDa estimated polypeptide in SDS-PAGE resulting from glycosylation. |
Purity: | Greater than 97% as determined by SDS-PAGE. |
Endotoxin: | < 1.0 EU per μg of the recombinant human EPO protein by the LAL method. |
Bioactivity: | The bio-activity of recombinant human EPO protein was determined by dose-dependent stimulation of the proliferationof TF-1 cells |
Formulation: | Recombinant human EPO protein was lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization |
Stability: | Recombinant Proteins are stable for up to 1 year from date of receipt at -70℃ |
Reconstitution: | Please see related COA for specific instructions. |
Storage: | Avoid repeated freeze-thaw cycles. In lyophilized state for 1 year (4-8℃); Upon reconstitution under sterile conditions for 2 weeks (4-8℃) or 3 months (-20℃ to -80℃). |